Intervention Review

You have free access to this content

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

  1. Giovanni FM Strippoli1,*,
  2. Elisabeth M Hodson2,
  3. Cheryl A Jones3,
  4. Jonathan C Craig4

Editorial Group: Cochrane Renal Group

Published Online: 17 FEB 2010

Assessed as up-to-date: 9 NOV 2005

DOI: 10.1002/14651858.CD005133.pub2

Database Title

Additional Information

How to Cite

Strippoli GFM, Hodson EM, Jones CA, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005133. DOI: 10.1002/14651858.CD005133.pub2.

Author Information

  1. 1

    c) Diaverum Medical Scientific office, d) Mario Negri Sud Consortium, Italy, a) School of Public Health, University of Sydney, b) Cochrane Renal Group, Westmead, NSW, Australia

  2. 2

    School of Public Health, The University of Sydney, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia

  3. 3

    The University of Sydney, Discipline of Paediatrics and Child Health, Westmead, Sydney, NSW, Australia

  4. 4

    (b) School of Public Health, The University of Sydney, (a) Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia

*Giovanni FM Strippoli, a) School of Public Health, University of Sydney, b) Cochrane Renal Group, c) Diaverum Medical Scientific office, d) Mario Negri Sud Consortium, Italy, Locked Bag 4001, Westmead, NSW, 2145, Australia. Giovanni.Strippoli@diaverum.com. strippoli@negrisud.it.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 FEB 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (59K)Standard (319K)Full (396K)
[Figure 1]
Figure 1. Flow-chart indicating the number of citations retrieved by individual searches and the final number of included trials; reasons for exclusions are provided.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 1 All symptomatic CMV disease.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 2 CMV organ involvement.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 3 CMV associated symptoms.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 4 Acute rejection.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 5 All-cause mortality and graft loss.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 6 Other infections.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Pre-emptive medication for CMV viraemia versus placebo or standard care, Outcome 7 Adverse effects.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 1 All symptomatic CMV disease.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 2 Acute rejection.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 3 All-cause mortality and graft loss.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Pre-emptive medication versus prophylaxis, Outcome 4 Adverse effects.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Oral versus IV ganciclovir, Outcome 1 All symptomatic CMV disease.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Oral versus IV ganciclovir, Outcome 2 All-cause mortality.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Oral versus IV ganciclovir, Outcome 3 Other infections.
View Full Article (HTML) Summary (59K)Standard (319K)Full (396K)